Triangletofacitinib 2% cream (NCT06698822)
tofacitinib 2% cream trial for Cutaneous T-Cell Lymphoma (NCT06698822). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with skin-biopsy-confirmed cutaneous T-cell lymphoma, stages IA, IB, or IIA, without significant blood involvement. At least two lesions must have resisted or returned after one standard treatment. Stage IIA has lymph-node restrictions.
The idea: tofacitinib blocks JAK signaling involved in immune activity and inflammation. Patients apply two-percent cream twice daily to up to five eligible lesions. Researchers assess safety and lesion response at twelve weeks; treatment extension is optional.
This phase 2 study plans 20 patients. Julia Dai leads at MD Anderson, Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.